Loading...

Steven Barriere, PharmD

Title(s)Clinical Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Address533 Parnassus Avenue
San Francisco CA 94117
Phone415-476-2352
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPharm.D.1973 Pharmacy

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infect Dis Ther. 2019 Sep; 8(3):445-452. Niederman MS, Lee PC, Barriere SL, Barnes CN, Castaneda-Ruiz B. PMID: 31372837.
      View in: PubMed   Mentions:
    2. Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. Diagn Microbiol Infect Dis. 2017 Mar; 87(3):268-271. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL. PMID: 28038840.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    3. Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates. Infect Dis Ther. 2016 Dec; 5(4):535-544. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL. PMID: 27718118.
      View in: PubMed   Mentions:
    4. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clin Infect Dis. 2015 Sep 15; 61 Suppl 2:S87-93. Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL. PMID: 26316562.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    5. Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrob Agents Chemother. 2015 Oct; 59(10):6170-4. Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME. PMID: 26248356.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun; 71(6):707-714. Worboys PD, Wong SL, Barriere SL. PMID: 25939708.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    7. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015 Feb; 16(2):151-3. Barriere SL. PMID: 25483564.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    8. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015 Mar 01; 60(5):787-96. Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. PMID: 25472944.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    9. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother. 2014 Dec; 58(12):7093-7. McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA. PMID: 25223996.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014 Dec; 80(4):327-9. Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. PMID: 25306423.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    11. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014 May 23; 14:289. Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere SL, Kitt MM, Corey GR. PMID: 24884578.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    12. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. Infect Drug Resist. 2014; 7:129-35. Rubinstein E, Stryjewski ME, Barriere SL. PMID: 24876786.
      View in: PubMed   Mentions:
    13. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis. 2014 Apr 04; 14:183. Barriere SL, Stryjewski ME, Corey GR, Genter FC, Rubinstein E. PMID: 24708675.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    14. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 2014; 9(3):281-9. Barriere SL. PMID: 24450506.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    15. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014; 58(4):2030-7. Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. PMID: 24419353.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    16. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2014; 38(2):235-40. Ero MP, Harvey NR, Harbert JL, Janc JW, Chin KH, Barriere SL. PMID: 24132401.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    17. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013 Oct; 42(4):367-9. Stryjewski ME, Barriere SL, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR. PMID: 23891527.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    18. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2012 Dec; 74(4):429-31. Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM. PMID: 23083812.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    19. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Nov; 56(11):5476-83. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR. PMID: 22869571.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    20. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012 Jun; 67(6):1496-502. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR. PMID: 22416054.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    21. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother. 2012 Apr; 56(4):2067-73. Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P. PMID: 22252798.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    22. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar; 50(3):848-56. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere SL, Fowler VG. PMID: 22205797.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    23. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis. 2011 Sep 01; 204(5):704-13. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG. PMID: 21844296.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    24. Effects of telavancin on coagulation test results. Int J Clin Pract. 2011 Jul; 65(7):784-9. Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. PMID: 21564449.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan 01; 52(1):31-40. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME. PMID: 21148517.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    26. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010 Dec; 5(12):1765-73. Barriere SL. PMID: 21080861.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    27. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis. 2010 Oct; 68(2):181-5. Krause KM, Barriere SL, Kitt MM, Benton BM. PMID: 20846593.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    28. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis. 2010 Aug 01; 51 Suppl 1:S4-9. Barriere SL. PMID: 20597670.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010 Aug; 30(8):806-11. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. PMID: 20653356.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    30. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb; 30(2):136-43. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. PMID: 20099988.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    31. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010 Jan; 30(1):35-42. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. PMID: 20030471.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    32. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol. 2009 Dec; 47(12):3952-7. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG. PMID: 19846653.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    33. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs. 2009 Oct; 32(10):745-51. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B. PMID: 19943236.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    34. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009 Jul; 49(7):816-23. Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. PMID: 19443680.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    35. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg. 2009 Jun; 197(6):791-6. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM. PMID: 19095213.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    36. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. PMID: 19025428.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    37. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008 Oct; 62(4):780-3. Wong SL, Barriere SL, Kitt MM, Goldberg MR. PMID: 18586659.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    38. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 01; 46(11):1683-93. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. PMID: 18444791.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCellsCTClinical Trials
    39. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008 Jul; 52(7):2300-4. Lodise TP, Gotfried M, Barriere S, Drusano GL. PMID: 18426898.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    40. Pharmacists and industry: guidelines for ethical interactions. Pharmacotherapy. 2008 Mar; 28(3):410-20. Hatton RC, Chavez ML, Jackson E, Maurey J, Barriere SL, Couchenour R, Evens RP, Gunning K, Hume AL, Hutchison LC, Matzke GR, Noviasky JA, Rospond RM, Kelloway JS, Stevenson JG, Vanderveen RP, Verme-Gibboney CN, Walters D. PMID: 18294122.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol. 2008 Feb; 46(2):678-84. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG. PMID: 18077636.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    42. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008 Jan; 52(1):92-7. Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. PMID: 17923490.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    43. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006 Mar; 50(3):862-7. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR. PMID: 16495243.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    44. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005 Jun 01; 40(11):1601-7. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR. PMID: 15889357.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    45. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004 Jul; 44(7):689-95. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. PMID: 15199073.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    Steven's Networks
    Concepts (181)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑